High grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

1 event
Mar 2018Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Mayo Clinic — PHASE2

TrialRECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

0

Total programs

No financial assistance programs currently listed for High grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement.
Check the disease page for updates →

Approved Treatments

1 FDA-approved

Epkinly

(epcoritamab-bysp)Orphan drugaccelerated

Genmab US, Inc.

Bispecific CD20-directed CD3 T Cell Engager [EPC]

12.1 Mechanism of Action Epcoritamab-bysp is a T-cell engaging bispecific antibody that binds to the CD3 receptor expressed on the surface of T-cells ...

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

1 active trial
1Phase 2
1Total recruiting
Search clinical trials for High grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement

Recent News & Research

No recent news articles indexed yet for High grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement.
Search PubMed for High grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement

Browse all High grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement news →

Specialist Network

Top 3 by expertise

View all High grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement specialists →

Quick Actions